Considering the potential confounding metabolic effects of PPARγ and GLP-1R agonists, it would be of utmost importance to identify effectors that specifically induce Ceacam1 promoter activity in an attempt to develop CEACAM1-targeted therapy with high efficacy against hepatic fibrosis and limited off-target effects. The gene discussed is GLP1R; the disease is Hepatic fibrosis.